Live feed09:00:00·1104dPRReleasevia QuantisnowIDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal MelanomaByQuantisnow·Wall Street's wire, on your screen.IDYA· IDEAYA Biosciences Inc.Health Care
